Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $74.26 and last traded at $74.26, with a volume of 313 shares trading hands. The stock had previously closed at $77.00.
Wall Street Analyst Weigh In
ZLDPF has been the subject of a number of recent research reports. Cantor Fitzgerald raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, January 21st. William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
Check Out Our Latest Analysis on ZLDPF
Zealand Pharma A/S Trading Down 14.6 %
The company has a 50-day moving average price of $97.60 and a two-hundred day moving average price of $109.37. The stock has a market cap of $6.00 billion, a P/E ratio of -35.81 and a beta of 0.92. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.19. The business had revenue of $1.30 million for the quarter, compared to analysts' expectations of $28.11 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. On average, research analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Stories
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
